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Abstract
Adeno-associated viral vectors are widely used as vehicles for gene transfer to the nervous system. The promoter and viral
vector serotype are two key factors that determine the expression dynamics of the transgene. A previous comparative study
has demonstrated that AAV1 displays efficient transduction of layer V corticospinal neurons, but the optimal promoter for
transgene expression in corticospinal neurons has not been determined yet. In this paper, we report a side-by-side
comparison between four commonly used promoters: the short CMV early enhancer/chicken β actin (sCAG), human
cytomegalovirus (hCMV), mouse phosphoglycerate kinase (mPGK) and human synapsin (hSYN) promoter. Reporter
constructs with each of these promoters were packaged in AAV1, and were injected in the sensorimotor cortex of rats and
mice in order to transduce the corticospinal tract. Transgene expression levels and the cellular transduction profile were
examined after 6 weeks. The AAV1 vectors harbouring the hCMV and sCAG promoters resulted in transgene expression in
neurons, astrocytes and oligodendrocytes. The mPGK and hSYN promoters directed the strongest transgene expression. The
mPGK promoter did drive expression in cortical neurons and oligodendrocytes, while transduction with AAV harbouring the
hSYN promoter resulted in neuron-specific expression, including perineuronal net expressing interneurons and layer V
corticospinal neurons. This promoter comparison study contributes to improve transgene delivery into the brain and spinal
cord. The optimized transduction of the corticospinal tract will be beneficial for spinal cord injury research.
Introduction
The corticospinal tract (CST) is an important descending
motor pathway controlling the movement of the limbs and
trunk. Damage to the CST results in paralysis. Repair of the
CST is limited because this motor pathway has a low
intrinsic neuronal capacity for axon regeneration. The axon
regeneration capacity of corticospinal neurons can be
enhanced by delivering regeneration-associated genes using
gene therapy (reviewed in [1–4]). Manipulation of the CST
of rats and mice is widely used to examine the neuron-
intrinsic mechanisms that underlie the failure of axon
regeneration.
The descending CST originates in the motor cortex. The
rodent motor cortex is relatively large and covers a big area
of the frontal cortex [5–7]. Layer V of the motor cortex
contains pyramidal neurons, which are the main motor
neurons of the CST. The axons of layer V corticospinal
neurons descend via the internal capsule towards the pyr-
amid in the rostral medulla. At the pyramidal decussation, a
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large proportion of the CST fibres cross over to the con-
tralateral part of the spinal cord. The fibres that are crossing
over project through the ventral part of the dorsal column to
innervate all lamina of the spinal cord, mostly interneurons
within lamina III–VII [8–10]. The small proportion of
rodent fibres that do not cross continue ipsilaterally in the
ventromedial- and lateral columns of the spinal cord to
innervate interneurons of lamina III–VI [11], and moto-
neurons in the ventral horn [12, 13]. The CST-innervated
motor neurons can stimulate muscles in the periphery to
control movements of the animal.
Recombinant adeno-associated viral vectors (AAVs) are
the preferred viral vectors to target neurons of the central
nervous system (CNS), and have been used in clinical trials
for several neurological disorders (reviewed in [14–16]),
highlighting that AAV is gaining increasing acceptance as a
vector for clinical gene delivery. There are different ser-
otypes of AAVs each exhibiting different cellular tropism.
The transduction efficiency of a specific cell type by an
AAV vector is dependent on interaction of the viral capsid
with cell surface receptors, cellular uptake and subsequent
release of the vector from endosomes, trafficking to the
nucleus and finally transcription and translation of the
transgene (reviewed in [17–19]). As discussed above, gene
therapy for axon regeneration within the CST should be
aimed at layer V pyramidal neurons of the motor cortex. A
direct side-by-side comparison of AAV vector serotypes
(with a CMV promoter) in the CST of rats revealed that
AAV1, followed by AAV5, is the most efficient serotype to
transduce layer V cortical neurons in rats after direct
injection [20]. Other studies that examined AAV serotypes
after direct injection into the rodent cortex also found that
AAV1 efficiently transduces cortical neurons [21–23].
The promoter is a major DNA regulatory element in the
viral vector genome that determines the level of transgene
expression and in which cells the transgene will be
expressed. The choice of promoter is therefore an essential
aspect of the design of AAV vectors. Furthermore, the size
of the promoter is also relevant as AAVs have a maximum
packaging capacity of ~4700 nucleotides. To date, a pro-
moter that results in strong and selective expression of
transgenes in layer V corticospinal neurons has not been
determined by a direct side-by-side comparison.
The aim of this study was to identify a promoter that
initiates strong transgene expression and is specific for
cortical neurons, preferably layer V corticospinal neurons.
We compared in rats and mice transgene expression under
four different promoters delivered by AAV1, including the
short variant of CMV early enhancer/chicken β actin
(sCAG) promoter, the human CMV (hCMV) promoter, the
mouse PGK (mPGK) promoter, and the human synapsin
(hSYN) promoter. These four promoters were chosen
because: (1) these are relatively compact promoters thus
allowing for the accommodation of relatively large trans-
genes; (2) these promoters have been used to transduce the
nervous system but their activity in the brain has not been
studied in a side-by-side comparison; and (3) the specific
requirement for a strong promoter in the large CST. This
AAV1 promoter comparison study contributes to the opti-




Vector plasmids were designed to investigate the expression
potential of different promoters (Fig. 1). AAV-sCAG-eGFP
was provided by the laboratory of Joost Verhaagen and is
described in [24]. AAV-hCMV-eGFP was a gift from
Connie Cepko (Addgene plasmid # 67634). AAV-mPGK-
eGFP was made by amplifying the eGFP sequence of AAV-
hCMV-eGFP by using the primers 5′ GGAATTC
ATGGTGAGCAAGGGCGAG 3′ and 5′ AGCGCTTTA
CTTGTACAGCTCGTCCATG 3′ and was then cloned into
an AAV-mPGK plasmid, which was a gift from Patrick
Aebischer (Addgene plasmid # 24593), via HindIII-HF
(NEB, R3104) and EcoRI-HF (NEB, R3101) digestion.
AAV-hSYN-eGFP was made by removing the WPRE from
plasmid pTRUF20B-SEW, a gift from Deniz Kirik (Lund
University) described in [25], by HincII (NEB, R0103)
digestion.
Cortical neuron cultures and magnetofection
Glass bottom cell culture dishes (Greiner bio-one, 627860)
were coated with 7.5 mg poly-D-lysine in 0.1 M borate
buffer (pH 8.5) overnight at room temperature, and were
washed with PBS the following day. Primary cortical neu-
ron cultures were prepared from embryonic day 18 Sprague
Dawley rats. The embryonic cortex was dissected in Hanks’
balanced salt solutions (HBBS) (Thermo Fischer Scientific,
14170) supplemented with a 10 mM HEPES (Thermo
Fischer Scientific, 15630106) using forceps. The neurons
were dissociated in 40 units of papain (Worthington,
LK003176) per dissected brain that was dissolved in
HBBS-HEPES for 10 min at 37 °C. Next, they were briefly
rinsed with DNase (Sigma-Aldrich, D5025) and washed
with HBSS-HEPES solution. The cortical tissue was care-
fully dissociated using different sizes of glass Pasteur pipets
and the tissue was applied through a 40 μm falcon cell
strainer (Thermo Fischer Scientific, 352340) to remove non-
dissociated cortical tissue. The dissociated neurons were
counted and ~300,000 cells were then cultured in neural Q
basal medium (Globalstem, gsm9420), supplemented with
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2% GS21 (Amsbio, gsm3100) and 1% glutamax (Thermo
Fischer Scientific, 35050061) on the poly-D-lysine coated
cell culture dishes. The cultured neurons were kept at 37 °C
in a 7% CO2 incubator.
The cortical neurons were transfected at 10 days in vitro
(DIV) using oscillating nanomagnetic transfection (mag-
nefect nano system; nanoTherics). The vector plasmids (7
μg per dish) were mixed with 8 μl of magnetic nano-
particles (NeuroMag, NM50200) in 100 μl of culture
medium without supplements and were incubated for 30
min. Afterwards the transfection mixture was topped up
with 900 μl of medium, and then cell culture media in the
dishes was substituted for the transfection mixture and the
dishes were placed over a magnetic array, moving laterally
at 2 Hz and at 0.2 mm amplitude of displacement for 30
min at 37 °C in a 7% CO2 incubator. After transfection, the
transfection mixture was removed and the original culture
medium was returned to each well. The neurons were then
cultured until 14 DIV. At this time point, the neurons were
fixed with 4% paraformaldehyde (PFA) in PBS for 10 min
at room temperature and afterwards washed with PBS. The
cells were mounted using FluorSaveTM reagent (Calbio-
chem, 345789) and by applying a 19 mm diameter round
coverslip.
Image acquisition and morphology analysis of
cultured cortical neurons
Images for fluorescent intensity analyses were captured on a
fluorescence microscope (DM6000 B, Leica) with a ×40-oil
objective. The images were taken with the soma in the
centre to be able to quantify the number of dendritic bran-
ches in series of circles with increasing radii. Semi-
automated and standardized analysis of the images was
performed using the MATLAB platform version 2017 and a
programme called SynD [26]. SynD detects the soma by
thresholding and component analysis. Afterwards, the pro-
gramme detects neurites by applying a steerable filter to the
image. Neurites that were not completely traced by the
programme were manually extended, while spines or debris
that were incorrectly identified as neurites were manually
erased. The following output of SynD was used: (1) the
average fluorescence of each neurite within a 100 μm dis-
tance from the soma, (2) soma fluorescence intensity, (3)
soma area and (4) dendritic sholl analysis.
Adeno-associated viral vector preparation
The small-scale production of recombinant AAVs was done
as described previously [27]. The titres of AAVs were deter-
mined by quantitative PCR on the viral genomic DNA. The
AAVs were titre matched to 1.42 × 1012 gc/ml before stereo-
tactic injections into the sensory-motor cortex of animals.
Animals and stereotactic injection of adeno-
associated viruses in the sensory-motor cortex
A total of 20 adult female rats (Lister Hooded, Charles
River Laboratories) and 20 adult female mice (C5BL/6,
Charles River Laboratories) were used in this study. The
animals were housed in groups and had access to water and
food ad libitum in standard laboratory conditions.
Fig. 1 Schematic
representation of adeno-
associated viral vectors. Four
vectors that express enhanced
green fluorescent protein (eGFP,
720 bp) under different
promoters. The short CAG
(sCAG) promoter is 868 bp
long. The human CMV (hCMV)
promoter has a size of 752 bp
and is upstream of a 400 bp β-
globin intron. The mouse PGK
(mPGK) promoter is 551 bp
long and is upstream of a 400 bp
β-globin intron. The shortest
promoter is human SYN (hSYN)
with a size of 499 bp. The
packaging cassettes are flanked
by inverted terminal repeats
(ITR). The poly-A signals are
not shown. bp base pairs.
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This research has been regulated under the Animals (Sci-
entific Procedures) Act 1986 Amendment Regulations 2012
following ethical review by the University of Cambridge
Animal Welfare and Ethical Review Body. All procedures
were performed using aseptic techniques. Viral vectors were
stereotactically injected into the right sensory-motor cortex of
mice and rats as described below. The animals were anes-
thetized with isoflurane (4% isoflurane in O2 for induction,
2% isoflurane for maintenance) delivered via a facemask and
received postoperative analgesia. Body temperature was kept
at roughly 36 °C via a heating pad with an anal probe. The
head of the animal was shaved and the skin was disinfected.
The animal was next placed in the stereotaxic frame (David
Kopf Instruments) were a midline incision was made to
expose the skull and holes were drilled at coordinates that
cover the right sensory-motor cortex (Fig. 2). A Hamilton
syringe with needle was positioned through the generated
holes and was lowered into the brain by 0.5 mm for mice and
1.5mm for rats. Thereafter, 0.5 μl of AAV vector was injected
in each hole at a rate of 0.2 μl per minute (total virus volume
of 2 μl per mice and 3.5 μl per rat) using a Micro4 micro
syringe pump controller. The needle was slowly removed
2min after injection to allow proper diffusion of the virus and
avoid unwanted leaking. Afterwards, the skin was sutured and
the animals were recovered at 37 °C before they were returned
to standard housing.
One rat (out of the 40 injected animals in total) that was
injected with AAV1-mPGK-eGFP was excluded from the
study because the stereotactic injections poorly covered the
sensory-motor cortex.
Histology
Six weeks after the injection of AAV vectors, animals were
euthanized by injecting an overdose of Euthatal followed by
transcardial perfusion with ice cold PBS followed by ice
cold 4% PFA in PBS. The brain and spinal cords were
collected and stored in 4% PFA in PBS for 24 h at 4 °C.
Afterwards, the tissue was stored in 30% sucrose in PBS
with 0.1% sodium azide at 4 °C until further use. The cer-
ebrum was cut into 40 μm tick coronal sections and the
spinal cords were cut in transverse sections with a thickness
of 40 μm using a freezing microtome. The cerebrum tissue
was collected in 12 series creating an anatomical distance of
480 μm between each section in one well (in other words,
section 1 was placed into well 1, section 2 was placed into
well 2, and this was done until section 12. Afterwards, this
process was repeated). The tissue was kept in a 12-well
plate containing PBS and 0.1% sodium azide at 4 °C in the
dark until further use.
Immunohistochemistry
The sectioned brains and spinal cords were washed with
PBS. Then the tissue was permeabilized and blocked by
applying 0.3% Triton X-100 (Sigma, X-100) and 10% goat
serum (Sigma-Aldrich, G9023) in PBS for 2 h at room
temperature. The tissue was then incubated with primary
antibodies that were diluted in above-mentioned blocking
detergent at 4 °C overnight. The primary antibodies used
were anti-eGFP (A10262, 1:1000, Thermo Fischer Scien-
tific or Ab290, 1:1000, Abcam), anti-NeuN (ABN91, 1:500,
Merck), anti-Aggrecan (AB1013, 1:400, Merck), anti-Glial
Fibrillary Acidic protein (Z0334, 1:500, Dako), anti-Iba1
(019–19741, 1:1000, Wako), anti-APC clone CC1 (OP80,
1:300, Merck), anti-Olig-2 (AB9610, 1:500, Merck). The
perineuronal net (PNN) marker Wisteria floribunda agglu-
tinin (WFA) was labelled by applying biotin-conjugated
lectin (L1516, 4 μg/ml, Merck) instead of a primary anti-
body. Afterwards, the tissues were washed and incubated in
Fig. 2 Injection coordinates for the sensory-motor cortex in the right
hemisphere of rats and mice. The 0 point of the XY graphs represents
Bregma and the coordinates were defined by their mediolateral (x) and
anteroposterior (y) position relative to Bregma. Each site was injected
with 0.5 μl of AAV vector. (Left) Rats were injected at seven
coordinates: +1.5, +1mm; +2, +3.5 mm; +2.5, +1.5 mm; +2.5,
+0.5 mm; +3.5, +2mm; +3.5, +0.5 mm, +3, −0.5 mm. The virus was
injected at a depth of 1.5 mm (z=−1.5 mm). (Right) Mice were injected
at four coordinates: +2, +1mm; +2, +0.5 mm; +2, −0.5 mm; +2,
−1mm. The virus was injected at a depth of 0.5 mm (z=−0.5 mm).
Optimization of adeno-associated viral vector-mediated transduction of the corticospinal tract:. . . 59
Alexa Fluor-conjugated secondary antibodies that were
diluted in 0.3% Triton X-100 and 10% goat serum in PBS
for 2 h at room temperature in the dark. The secondary
antibodies used were anti-chicken IgY conjugated to Alexa
Fluor 488 (A-11039, 1:500, Thermo Fischer Scientific),
anti-chicken IgY conjugated to Alexa Fluor 568 (A-11041,
1:500, Thermo Fischer Scientific), anti-rabbit IgG con-
jugated Alexa Fluor 488 (A-11008, 1:500, Thermo Fischer
Scientific), anti-rabbit IgG conjugated Alexa Fluor 568
(A-11011, 1:500, Thermo Fischer Scientific), anti-rabbit
IgG conjugated Alexa Fluor 647 (A-21245, 1:500, Thermo
Fischer Scientific), anti-mouse IgG2b conjugated Alexa
Fluor 568 (A21144, 1:500, Thermo Fischer Scientific).
WFA was visualized by applying streptavidin conjugated
Alexa Fluor 568 (S11226, 1:500, Thermo Fischer Scien-
tific) to the tissue. After washing, the free-floating sections
were mounted using FluorSaveTM reagent (Calbiochem,
345789) on glass imaging slides.
Microscopy
Cultured cortical neurons were imaged on a fluorescence
microscope (DM6000 B, Leica) with a ×40-oil objective
using Leica software for quantifications. Representative
images of cultured cortical neurons were taken using an SP5
confocal microscope with a ×40-oil objective and a 2.5
digital zoom factor using Leica software. Fluorescent tissue
slides stained for NeuN were scanned on a Zeiss AxioScan
Z1 (Histopathology core facility in Cancer Research UK—
Cambridge institute) using a ×20 light objective. Images
containing the regions of interest were exported in TIFF
format. All images within an experiment were taken with
identical settings when the eGFP intensity was quantified.
Representative images for astrocytes, microglia, the oligo-
dendrocytes lineage, neurons with PNNs and the dCST
were taken using laser-scanning confocal microscopy
(Leica, TCS SPE, DMI4000B).
Quantification of histological samples
The mean area of transduction per section was measured in
ImageJ by manually outlining the area that contained eGFP-
positive staining. The transduction area reported for each
animal is the average taken from two sections per animal
with the biggest transduction area.
The number of transduced cortical neurons (eGFP+
NeuN+ cells) and the mean eGFP intensity per transduced
neuron was measured using a custom-made ImageJ Macro
(Supplementary Table 1) and data-processing spreadsheet
to process the ImageJ output (Supplementary Data 1).
Importantly, the numbers reported for each animal are the
average taken from two sections with the biggest trans-
duction area. The ImageJ macro automatically detects
round cells that are present in the red channel of an image
(e.g. NeuN+ cells) and then measures the fluorescent
intensity of all marked cells in the green channel (e.g.
eGFP). Afterwards, manual eGFP intensity measurements
of three non-transduced cells were done to set a threshold
for the background signal in non-transduced neurons.
In addition, manual eGFP intensity measurements were
taken in between multiple transduced somata within the
region of interest to set the background threshold within
the transduced area. After applying the Macro and com-
pletion of the two background measurements, the number
of transduced neurons and the mean eGFP intensity per
transduced neuron were calculated in the data-processing
spreadsheet. Cells were automatically classified as trans-
duced cortical neurons when the eGFP fluorescent inten-
sity was higher than an arbitrary limit of 30% above
the average background intensity of the transduced
area. Because each brain was cut into a series of 12, the
number of transduced cortical neurons of each image was
multiplied by 12 to obtain the total expected number of
transduced neurons per section covering ~480 μm in
anteroposterior direction. The mean eGFP intensity of
transduced cortical neurons was calculated by taking the
average eGFP intensity of these neurons and afterwards
subtracting the average eGFP intensity of three non-
transduced cells chosen at random within the same
section. To examine whether our analysis pipeline was
correctly calibrated, we performed manual analysis of ten
random cropped images of AAV transduced cortical tissue
and compared this with the new analysis method. There
was no statistically significant difference in the number
of transduced cortical neurons between the manual
counts (defined as 100%) and the ImageJ analysis pipeline
(112 ± 9.5% fraction of normalized cells) (Supplementary
Fig. 1), validating this quantification method for the
number of transduced cortical neurons.
The number of eGFP-containing axons in the dCST was
manually counted by using microscope eyepiece reticles
(Pyser Optics, NE11A—01B26210) and a standard fluor-
escence microscope (DM6000 B, Leica) with ×63-oil
objective. The squared grid covered a region of 80 × 80 μm
with this magnification. Axon transduction for each animal
was determined by taking the average number of green
fluorescent axons in three counting grids. This average
number was multiplied by factor 10 or 4 for rats or mice,
respectively, to cover the transduced dCST at the cervical
spinal cord. Confocal images with ×63-oil objective were
taken to measure the eGFP intensity of the transduced
axons. The mean eGFP intensity was determined by taking
the average fluorescent intensity of ten axons and sub-
tracting one background measurement.
The number of transduced PNN-bearing interneurons
was manually counted from images taken with a standard
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fluorescence microscope (DM6000 B, Leica) with ×40-oil
objective. The images covered a physical length of 320 × 240
μm. The number of transduced PNN-bearing interneurons for
each animal was determined by taking the average number of
eGFP+ cells that were surrounded by WFA (Alexa 568) and/
or Aggrecan (Alexa 647) staining in six images of two sec-
tions with the biggest area of AAV transduction.
The number of transduced astrocytes and microglia were
manually counted by using microscope eyepiece reticles
(Pyser Optics, NE10A—01B26208) and a standard fluor-
escence microscope (DM6000 B, Leica) with ×40-oil
objective. The squared grid covered a region of 250 × 250
μm with this magnification. The transduced cells were
visualised by using a filter that permits both green (Alexa
488) and red (Alexa 568) fluorescent light through the
eyepiece. The number of transduced cells per ROI for each
animal was calculated by taking the average number of
transduced cells in three counting grids of two sections with
the biggest area of AAV transduction.
The number of transduced cells from the oligodendrocyte
lineage was manually counted from images taken with a
standard fluorescence microscope (DM6000 B, Leica) with
×63-oil objective. The images covered a physical length of
203 × 152 μm. The number of transduced cells for each
animal was determined by taking the average of the number
of Olig2+ eGFP+ cells in three images of the section with
the largest area of AAV transduction in the corpus
callosum.
Statistical analysis
Statistical analysis was performed by using Graphpad
Prism 7 for Mac OS X. All statistical tests and parameters
are mentioned in the figure legends. The graphs represent
the average for each condition together with the individual
data points for each animal, rather than error bars, because
of the relatively small N numbers per group used in this
study [28]. The Shapiro–Wilk test was used to test
normality and the Brown–Forsythe test was performed to
examine equality of group variances. Comparisons
between two experimental groups (e.g. AAV1 and AAV5)
were done using an unpaired t-test or Mann–Whitey test
depending on the distribution of the variables. Compar-
isons between more than two experimental groups (e.g.
four promoters) and one measured variable were done
using One-way ANOVA and Tukey’s multiple compar-
ison test or Kruskal–Wallis test and Dunn’s multiple
comparison test depending on the distribution of var-
iances. For the sholl analysis of neurite branches, we used
a repeated measure ANOVA test since an interaction
between the two independent variables ‘number of bran-
ches’ and ‘distance from soma’ is examined between four
experimental groups.
Results
Validation of gene expression from the AAV vector
plasmids in cortical neurons in vitro
The plasmids were transfected in cortical neurons in vitro,
before AAV vectors were produced, to validate that the
cloned plasmids are functional in these cells. Each of the
four plasmids resulted in eGFP expression after transfection
(Fig. 3a), validating the functionality of the AAV vector
plasmids in primary cortical neurons. The strength of the
four promoters in vitro was also determined by measuring
the intensity of eGFP. Four days after the transfection, the
eGFP intensity was similar between the sCAG, hCMV,
mPGK and hSYN promoters (Fig. 3b, c). The eGFP
intensity is high in the soma (Fig. 3c) as the fluorescent
protein is synthesized here after plasmid transfection. As
expected, the investigated primary cortical neurons had a
similar neuronal morphology in all experimental groups
(Fig. 3d, e).
Efficiency of the four promoters to express eGFP in
cortical neurons in vivo
A previous study comparing multiple AAV serotypes har-
bouring a CMV promoter showed that AAV1 is the most
efficient serotype to transduce the CST in rats [20]. We
compared AAVs serotypes 1 and 5 with an hSYN promoter
and confirmed that AAV1 is superior over AAV5 to trans-
duce cortical neurons (Supplementary Fig. 2) and layer V
corticospinal neurons (Supplementary Fig. 3) in rats and mice.
We next decided to determine the optimal promoter for
transgene expression in the sensorimotor cortex and CST
using the AAV1 serotype. AAV1-sCAG-eGFP, AAV1-
hCMV-eGFP, AAV1-mPGK-eGFP and AAV1-hSYN-eGFP
were injected into the right sensory-motor cortex of rats and
mice for this purpose (see Fig. 2 for injection sites). The
transduction area, the number of transduced neurons and the
expression intensity of eGFP were measured 6 weeks after
AAV injection.
In rats (Fig. 4a), the mean area of transduction in cortical
sections was significantly different between the four pro-
moters. The AAV1 vectors with the mPGK and hSYN
promoter had an average transduction area of ~1 mm2
(1.24 ± 0.14 and 1.03 ± 0.17 mm2, respectively), whereas
the vectors with sCAG and hCMV transduced an area of
0.55 mm2 (0.59 ± 0.09 and 0.55 ± 0.09 mm2, respectively)
(Fig. 4b). A difference between the four experimental
groups was also observed when analysing the number of
transduced neurons. The AAV1 vector with mPGK and
hSYN promoters transduced on average the highest
number of cortical neurons (7950 ± 477 and 6473 ± 682
NeuN+ cells per section, respectively) followed by sCAG
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and hCMV (2172 ± 189 and 1256 ± 277 NeuN+ cells
per section, respectively) (Fig. 4c). Importantly, not only
the number of transduced neurons was higher with the
mPGK and hSYN promoters but these promoters also
resulted in significantly higher levels of eGFP expression
in cortical neurons (80 ± 6 and 69 ± 3 a.u., respectively)
compared with the sCAG and hCMV promoters (18 ± 2
and 26 ± 3 a.u., respectively) (Fig. 4d).
In mice (Fig. 5a), the mean area of transduction in cor-
tical sections was also statistically different between
the four promoters. The AAV1 vector carrying the
hSYN promoter (1.03 ± 0.10 mm2) had the biggest area of
transduction compared with the other promoters (mPGK,
0.62 ± 0.09 mm2; sCAG, 0.44 ± 0.11 mm2; hCMV, 0.40 ±
0.07 mm2) (Fig. 5b). The vector with the hSYN promoter
transduced the highest number of cortical neurons (4098 ±
252 NeuN+ cells per section), while the vector with the
mPGK promoter resulted in the second highest mean number
of transduced neurons (3464 ± 530 NeuN+ cells per section).
This was followed by sCAG and hCMV (1704 ± 665 and
1962 ± 387 NeuN+ cells per section, respectively) (Fig. 5c).
Importantly, the eGFP intensity was also different between
the four promoters. The AAV vectors with the mPGK and
hSYN promoters expressed eGFP with the highest intensity in
neurons (73 ± 10 and 65 ± 2 a.u., respectively). The vectors
with the sCAG and hCMV promoters had relatively low
eGFP intensity in cortical neurons (28 ± 8 and 42 ± 8 a.u.,
respectively) (Fig. 5d).
In summary, the most efficient promoters for AAV1-
mediated transgene expression in cortical neurons are
mPGK and hSYN in rats and mice.
Efficiency of the four promoters to transduce layer V
corticospinal neurons in vivo
After confirming successful transduction of neurons in the
cortex, we examined whether the AAVs also transduce
layer V cortical neurons that give rise to the CST. To
highlight successful transduction of the CST, representative
images at the medullary pyramid and cervical spinal cord
were taken from tissue injected with AAV1-hSYN-eGFP.
As expected, eGFP-positive axons were found to be
crossing at the pyramidal decussation and descending into
the left dorsal columns of the spinal cord (Fig. 6a). Trans-
duced dCST collaterals were visible in various lamina of the
spinal cord, and eGFP-positive axons were also observed in
the ipsilateral ventral CST component (Supplementary
Fig. 4). To obtain the transduction efficiency of layer V
Fig. 3 Comparison of eGFP expression driven by each of the four
promoters in cultured cortical neurons transfected with AAV
vector plasmids. Intrinsic eGFP was measured. a Representative
images of 14 DIV cortical neurons that were transfected with four
different plasmids: sCAG-eGFP, hCMV-eGFP, mPGK-eGFP, hSYN-
eGFP. b Quantifications of the mean eGFP intensity in neurites (df= 3
(8), F= 0.23, p > 0.05, ANOVA). c Quantification of the mean eGFP
intensity in the soma (df= 3(8), F= 1.39, p > 0.05, ANOVA).
d Quantification of the soma area (df= 3(8), F= 0.41, p > 0.05,
ANOVA). e Sholl analysis of neurite branches (df= 3(8), F= 0.52,
p > 0.05, Repeated measure ANOVA, n= 3 per group). Data are
shown as average ± SEM. The results are obtained from three inde-
pendent experiments (n= 3) and a total of 45 transfected neurons
were analysed for each condition. Images were taken with identical
microscope settings between the experimental groups. Ns not statis-
tically significant.
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corticospinal neurons by AAV1 vectors with different
promoters, the number of eGFP-expressing axons and
fluorescent intensities were measured in the dorsal column
of transverse sections of the cervical spinal cord.
In rats (Fig. 6b, c), mPGK and hSYN had the best
transduction of layer V cortical neurons as 1497 ± 99 and
1305 ± 123 axons, respectively, were detected in the dorsal
column of the cervical spinal cord contralateral to the
injected sensory-motor cortex. The sCAG group counted
623 ± 50 green axons, and hCMV resulted on average in
293 ± 49 eGFP-positive fibres in the spinal cord. The
fluorescent intensity of the transduced axons was also
highest with the mPGK and hSYN promoters (172 ± 12.5
and 189 ± 11.5 a.u., respectively), and lowest with the
sCAG and hCMV promoters (31 ± 4.3 and 19 ± 1.6 a.u.,
respectively) (Fig. 6b, e).
In mice (Fig. 6b, d), 484 ± 30 and 386 ± 70 axons were
fluorescent in the spinal cord in the mPGK and hSYN
groups, respectively. The sCAG and hCMV promoters had
175 ± 47 and 95 ± 34 axons containing eGFP, respectively.
The fluorescent intensity of the transduced axons was
higher in the mPGK and hSYN conditions (144 ± 29.3 and
162 ± 26.4 a.u., respectively) compared with sCAG and
hCMV (31 ± 4.3 and 19 ± 1.6 a.u., respectively) (Fig. 6b, f).
The transduction efficiency and fluorescent intensities of
the AAV1 vector carrying the mPGK and hSYN promoters
Fig. 4 Neuronal transduction efficiency and mean eGFP intensity of
four promoters in the sensory-motor cortex of rats. a NeuN and
eGFP staining in the cortex of AAV1-sCAG-eGFP, AAV1-hCMV-
eGFP, AAV1-mPGK-eGFP and AAV1-hSYN-eGFP injected rats.
b Quantification of the mean area of transduction in 40 μm thick sections
(df= 3(11), F= 6.88, p < 0.01, ANOVA with Tukey’s multiple com-
parison test). c Quantification of the number of transduced NeuN+ cells.
eGFP+ NeuN+ cells were detected using the analysis pipeline and
neurons were considered as transduced when the eGFP intensity was
1.3× higher than the eGFP to background intensity ratio (df= 3(11), F=
50.4, p < 0.001, ANOVA with Tukey’s multiple comparison test).
d Quantification of the mean eGFP intensity per transduced neuron (df=
3(12), F= 107, p < 0.001, ANOVA with Tukey’s multiple comparison
test). The grey bars depict the averages and each dot represents the mean
value of one animal. A total of four rats were analysed for the sCAG,
hCMV and hSYN conditions, while three rats were analysed for the
mPGK condition. Images were taken with identical microscope settings
between the experimental groups. *p < 0.05; **p < 0.01; ***p < 0.001.
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were not statistically different indicating that these two
promoters are equally strong in both rats and mice. Fewer
and less bright eGFP-positive axons were observed in the
groups that contained the AAV1 vector harbouring the
sCAG and hCMV promoters indicating that these promoters
are less efficient to target the CST in vivo.
Efficiency of the four promoters to transduce
cortical neurons with PNNs in vivo
We also investigated whether PNN-bearing interneurons,
another important class of cortical neurons, were transduced
by the viral vectors injected in the sensorimotor cortex. The
transduction of these neurons was determined by counting
the number of eGFP-positive cells that were covered by
PNNs, which were visualized by immunohistochemistry for
WFA and aggrecan. The AAV1 serotype with all four
promoters were able to transduce interneurons with PNNs in
rats and mice (Fig. 7a). The promoters sCAG (12 ± 2 and
14 ± 6) and hCMV (41 ± 2 and 21 ± 1) had eGFP expression
in a relatively low number of PPN-bearing interneurons
(Fig. 7b, c). The mPGK (71 ± 10 and 60 ± 7) and hSYN
(88 ± 16 and 65 ± 13) promoters had the highest transduc-
tion of this class of neuron (Fig. 7b, c).
Fig. 5 Neuronal transduction efficiency and mean eGFP intensity
of four promoters in the sensory-motor cortex of mice. a NeuN
and eGFP staining in the cortex of AAV1-sCAG-eGFP, AAV1-
hCMV-eGFP, AAV1-mPGK-eGFP and AAV1-SYN-eGFP injected
mice. b Quantification of the mean area of transduction in 40 μm
thick sections (df= 3(12), F= 9.29, p < 0.01, ANOVA with
Tukey’s multiple comparison test). c Quantification of the number of
transduced NeuN+ cells. eGFP+ NeuN+ cells were detected using
the analysis pipeline and neurons were considered as transduced
when the eGFP intensity was 1.3× higher than the eGFP to back-
ground intensity ratio (df= 3(12), F= 5.74, p < 0.05, ANOVA with
Tukey’s multiple comparison test). d Quantification of the mean
eGFP intensity per transduced neuron (df= 3(12), F= 7.58, p <
0.01, ANOVA with Tukey’s multiple comparison test). The grey
bars depict the averages and each dot represents the mean value of
one animal. A total of four mice were analysed for each condition.
Images were taken with identical microscope settings between the
experimental groups. *p < 0.05; **p < 0.01.
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Fig. 6 Transduction efficiency
of AAV1 with four different
promoters in layer V
corticospinal neurons
measured by quantifying their
eGFP+ axons in the spinal
cord at cervical level 4. The
sections were stained for eGFP.
a Transduction of the CST in a
mouse injected with AAV1-
hSYN-eGFP. eGFP-positive
fibres are found crossing at the
level of the medullary pyramid
from the right to left brain
hemisphere (left), and the axonal
fibres are found in the left dorsal
columns of the cervical spinal
cord (right). b eGFP-positive




injected rats and mice.
c, d Quantification of the
number of transduced axons in
rats (df= 3(11), F= 43.7, p <
0.001, ANOVA with Tukey’s
multiple comparison test) and
mice (df= 3(12), F= 14.2, p <
0.001, ANOVA with Tukey’s
multiple comparison test).
e, f Quantification of the mean
eGFP intensity of the axon in
rats (df= 3(11), F= 121, p <
0.001, ANOVA with Tukey’s
multiple comparison test) and
mice (df= 3(12), F= 11.7, p <
0.001, ANOVA with Tukey’s
multiple comparison test). The
overview images were taken
with a tile-scanning
epifluorescence microscope,
while the zoom-in pictures were
taken using a confocal
microscope. The grey bars
depict the averages and each dot
represents the mean value of one
animal. Images were taken with
identical microscope settings
between the eight experimental
groups. *p < 0.05; **p < 0.01;
***p < 0.001.
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Expression of eGFP in the oligodendrocyte lineage
depending on the promoter in vivo
The stereotactic injections of AAVs also resulted in transgene
expression in the corpus callosum area; the transduction of
the oligodendrocyte lineage was therefore examined as well.
In our experiments, the clone CC1 antibody resulted in poor
visualization of matured oligodendrocytes in rats (Fig. 8—
left) and relatively high background staining in the corpus
callosum of mice (Fig. 8—right). The anti-Olig2 antibody
that labels the entire oligodendrocyte lineage was relatively
consistent in both animal species (Fig. 8a–d), and was
therefore used to quantify the number of transduced cells.
The injection of AAV1 with sCAG (Fig. 8a), hCMV
(Fig. 8b) and mPGK (Fig. 8c) promoters resulted in eGFP
expression in the oligodendrocyte lineage in the corpus cal-
losum of rats and mice. The sCAG (356 ± 65 and 340 ± 40)
and hCMV (362 ± 32 and 266 ± 38) promoters transduced
the highest number of OliG2-positive cells, while the mPGK
promoter (99 ± 57 and 177 ± 33) had relatively few cells
transduced in the corpus callosum (Fig. 8e, f). AAV1 with
hSYN promoter did not transduce cells from the oligoden-
drocyte lineage, but clear bundles of eGFP+ axons were
visible in the corpus callosum (Fig. 8d–f).
Expression of eGFP in astrocytes depending on the
promoter in vivo
The transduction of astrocytes was determined by counting
the number of GFAP-positive cells in the cortex that
expressed eGFP. Astrocyte transduction was determined for
the AAV1-sCAG-eGFP, AAV1-hCMV-eGFP, AAV1-
mPGK-eGFP and AAV1-hSYN-eGFP transduced brains
(Fig. 9a). The viral vectors containing the sCAG (92 ± 5 and
103 ± 26) and hCMV (36 ± 5 and 78 ± 11) promoter
induced eGFP expression in astrocytes within the injected
cerebral hemispheres of rats and mice (Fig. 9b, c). In con-
trast, the AAV1 vectors harbouring the mPGK and hSYN
promoter did not result in eGFP expression in astrocytes for
rats and mice (Fig. 9b, c).
No transduction of microglia using AAV1 with sCAG,
hCMV, mPGK and hSYN promoters in vivo
The number of transduced microglia was determined by
counting the number of Iba1-positive cells that expressed
eGFP in the cerebral cortex. The AAV1 serotype together with
the promoters sCAG, hCMV, mPGK and hSYN did not result
in expression of eGFP in microglia in rats and mice (Fig. 10).
Fig. 7 Transduction efficiency
of PNN-bearing interneurons
depending on the promoters
sCAG, hCMV, mPGK and
hSYN. a WFA (red), Aggrecan
(blue) and eGFP (green) staining




injected rats and mice.
b, c Quantification of the
number of transduced PNN-
bearing interneurons in rats (p <
0.001, Kruskal–Wallis test with
Dunn’s multiple comparison
test) and mice (df= 3(12), F=
10.4, p < 0.01, ANOVA with
Tukey’s multiple comparison
test). The grey bars depict the
averages and each dot represents
the mean value of one animal.
Arrows highlight transduced
PNN-bearing interneurons.
Microscope settings for the
eGFP intensity are not identical
between the experimental
groups in order to improve the
visualisation of transduced
PNN-bearing neurons; the
intensity settings for WFA and
aggrecan are identical
throughout the representative
images. *p < 0.05; **p < 0.01.
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Fig. 8 Expression of eGFP in
the oligodendrocyte lineage
with AAV1 and the promoters
sCAG, hCMV and mPGK, but
not with hSYN. The upper
panels illustrate an overview of
the right cerebral hemisphere
that was injected with AAV1
and four different promoters
expressing eGFP. The lower
panels are magnification images
taken at the inset in the upper
panels showing a portion of the
corpus callosum. The 40 μm
thick brain sections were stained
for clone CC1 (red), Olig2
(blue) and eGFP (green) in both




eGFP (c) and AAV-hSYN-eGFP
(d). e, f Quantification of the
number of transduced Olig2+
cells in rats (df= 2(8), F= 7.22,
p < 0.05, ANOVA with Tukey’s
multiple comparison test for
sCAG vs hCMV vs mPGK) and
mice (df= 2(9), F= 4.88, p <
0.05, ANOVA with Tukey’s
multiple comparison test for
sCAG vs hCMV vs mPGK).
Arrows highlight examples of
transduced cells in the
oligodendrocyte lineage for
sCAG, hCMV and mPGK,
while no transduced
oligodendrocytes are in the
hSYN experimental group.
Microscope settings for the
eGFP intensity are not identical
between the experimental
groups in order to improve the
visualisation of the transduced
oligodendrocyte lineage; the
intensity settings for CC1 and
Olig2 are identical
throughout the representative
images. *p < 0.05.
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Discussion
The aim of this study was to characterize expression driven
by popular promoters to optimize transduction of layer V
corticospinal neurons of the rat and mouse. The viral vector
serotype and the promoter are two variables that are known
to have a significant effect on the transduction efficiency of
AAV vectors. AAV1 is known to be a strong serotype to
transduce corticospinal neurons. Subsequently, we examined
the impact of the promoter by comparing AAV1 vectors
harbouring sCAG, hCMV, mPGK or hSYN promoter. The
results show that (1) the mPGK and hSYN promoters acti-
vated transgenes in significantly more neurons than the
sCAG and hCMV promoters, (2) mPGK and hSYN directed
higher levels of transgene expression in neurons than the
sCAG and hCMV promoters and (3) the hSYN promoter
mediated neuron-specific transgene expression, whereas the
sCAG, hCMV and mPGK promoters directed transgene
expression in both neurons and non-neuronal cells. These
results will be of use for the design of AAV-based gene
transfer experiments in corticospinal neurons, which form a
widely used fibre tract for studies on long-distance axon
regeneration in the injured spinal cord. Table 1 summarizes
the cellular transduction profile of AAV1 with the four
promoters investigated in this study.
Comparison of promoters in cultured cortical
neurons after transfection
The functionality of the vector plasmids was validated in
cultured cortical neurons by magnetofection prior to AAV
production. We choose this transfection method (rather than
viral transduction), because this approach is commonly used
in primary cortical culture experiments aiming to study indi-
vidual neurons [29, 30]. The time point of transfection
(10 DIV) and analysis (14 DIV) are typically chosen to study
matured cortical neurons derived from embryonic day 18
embryos [29, 30]. Interestingly, we did not find a difference in
fluorescence intensity between the four promoters in vitro.
The short cytosolic protein eGFP is rapidly synthesized after
plasmid transfection, which could explain no detectable dif-
ferences between the promoters for this fluorescent marker at
4 days after transfection. The eGFP intensities in the soma are
close to saturation levels, however, we had to use these
microscope settings to visualise neurites of the cultured neu-
rons. It is important to note that plasmid transfection is not a
delivery method that is comparable with the AAV transduc-
tion in vivo; we performed these experiments solely to test
plasmid functionality before virus production. The in vitro
results are not meant to be predictors for the efficacy in vivo.
Furthermore, the cultured cortical neurons are derived from
Fig. 9 Expression of eGFP in
astrocytes with sCAG and
hCMV promoters, but not
with mPGK and hSYN
promoters. a GFAP (red) and




eGFP injected rats and mice.
b, c Quantification of the
number of transduced GFAP+
cells in rats (df= 6, t= 7.97, p
< 0.001, Student’s t test for
sCAG vs hCMV) and mice (df
= 6, t= 0.87, p > 0.05,
Student’s t test for sCAG vs
hCMV). The grey bars depict
the averages and each dot
represents the mean value of one
animal. Arrows highlight
transduced astrocytes.
Microscope settings for the
eGFP intensity are not identical
between the experimental
groups in order to improve the
visualisation of transduced
astrocytes; the intensity setting
for GFAP is identical throughout
the representative images.
ns not significantly different;
***p < 0.001.
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embryonic tissue, which have a high rate of metabolic and
transcriptional activity that could allow the ubiquitous acti-
vation of various promoters, while this is more selective in
adult cortical neurons.
Analysis pipeline for semi-automated analysis of
eGFP+ NeuN+ cells in AAV transduced cortex
Manual analysis of microscope images containing thou-
sands of neurons is time-consuming and prone to human
bias and inconsistency. Manually quantifying the number
of AAV transduced neurons along with the eGFP fluores-
cence intensity could therefore be a challenging task. We
developed a semi-automated quantification method in the
form of a custom analysis pipeline consisting of an ImageJ
macro and a data-processing spreadsheet.
The analysis pipeline was compared with manual counts
on ten cropped images and we found no statistically sig-
nificant difference between the two groups (Supplementary
Fig. 1), validating the analysis pipeline. However, the
ImageJ macro does have some limitations. The user has to
set an arbitrary eGFP-to-background intensity ratio that will
be used to determine whether a round (NeuN+) cell is
eGFP positive or not. This arbitrary threshold is designed to
prevent false positives from non-transduced cells that
overlap with eGFP-positive branches (e.g. transduced den-
drites or astrocytes). We cannot exclude that transduced
non-neuronal cells, especially under the AAV1-sCAG and
AAV1-hCMV experimental conditions, have resulted in an
overestimation in the number of transduced neurons using
the analysis pipeline. The ImageJ macro is also limited to
the detection of round structures only (e.g. NeuN-positive
cells or DAPI and Hoechst stains), and in its current form
cannot be applied to detect more complex morphologies
such as astrocytes, microglia and PNNs.
The AAV1 serotype for transduction of the
corticospinal tract and cortex
The AAV1 serotype is commonly used to transduce the
CST via intracortical injections [31–38]. An earlier study
that compared seven AAV serotypes (AAV1–AAV6, and
AAV8) identified AAV1 and AAV5 as the best and second-
best serotypes to transduce the CST in rats [20]. Consistent
with that study, we found in both mice and rats that AAV1
transduces almost twice as many cortical neurons and layer
V corticospinal neurons as AAV5 (Supplementary Figs. 2,
3), highlighting that AAV1 is superior to AAV5 for trans-
duction of the CST and cortex. We also observed that
AAV1 harbouring an hSYN promoter directs a stronger
Fig. 10 AAV1 with the selected
four promoters did not have
tropism for microglia. a Iba1
(red) and eGFP (green) staining




injected rats and mice.
b, c Quantification of the
number of transduced Iba+ cells
in rats and mice. Each dot
represents the mean value of one
animal. Microscope settings for
the eGFP intensity are not
identical between the eight
experimental groups; the
intensity setting for Iba1 is
identical throughout the
representative images.
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expression of eGFP than AAV5 with this promoter (Sup-
plementary Figs. 2, 3). This difference may be caused by
the entry of more copies of the AAV1 than the AAV5
vector into cortical neurons. Both AAV serotypes bind to
α2–3 and α2–6 N-linked sialic acids [39–42], but their
endocytosis requires different cellular co-receptors. For
instance, AAV1 interacts with integrins [43], while AAV5
uses platelet-derived growth factor receptor as co-receptor
for transduction [24]. Furthermore, AAV1 and AAV5 bind
to different domains of the adeno-associated virus receptor
on the cell surface to initiate transduction [44]. The
endosomal processing of the viral vector particles inside the
cell, and de-capsidation and release of the viral genome
into the cell nucleus is also different between the two ser-
otypes [45–47].
An alternative approach to transduce the CST is by using
AAVs that have retrograde transduction properties and
inject them directly into the spinal cord. AAV6 [48] and a
directed evolved variant of AAV2 named ‘AAV2-Retro’
[49] have the capability for retrograde transduction in the
CNS. AAV2-retro has been applied for robust transduction
of the CST by injection into the spinal cord of adult mice
[50, 51].
Comparison of four promoters for transgene
expression
This study consists of a direct side-by-side comparison
between AAV1 vectors harbouring four compact promoters
for their ability to drive transgene expression in the CST
and cortex. The in vivo findings for each promoter are
discussed below.
The hSYN promoter resulted in neuron-specific trans-
gene expression and this corroborated previous studies
using this promoter [21, 33, 52–57]. One study reported that
the synapsin promoter is the most selective promoter among
five neuron-specific promoters that were tested in the rat
brain [56]. We found that the hSYN-driven transgenes were
activated in various subpopulations of cortical neurons, as
we observed expression in multiple cortical layers including
layer V pyramidal neurons and PNN-expressing neurons.
The hSYN promoter is also one of the experimental groups
with the strongest eGFP expression in vivo. To our
knowledge, there is no promoter available that is specific for
layer V pyramidal neurons that give rise to the CST. Thus,
the hSYN promoter is currently the promoter of choice to
drive transgene expression in corticospinal neurons,
because it is small (allowing large coding sequences to be
inserted), strong and neuron specific.
We found that the mPGK promoter in AAV1 directed
strong neuronal expression and limited transgene
expression in oligodendrocytes. Others have found rela-
tively similar results; a lentivirus with the mPGK pro-
moter injected into the sensorimotor cortex [58],
hippocampus [59], striatum [59] and substantia nigra
[60, 61] confirmed that this promoter preferentially
expresses in neurons rather than non-neuronal cells. In
contrast to our study using AAV1, one of the lentivirus
studies reported low tropisms for astrocytes using the
mPGK promoter [61]. A study that used the human PGK
promoter with AAV serotypes 6, 9, and rh10 reported
predominant expression in neurons and a limited number
of astrocytes and oligodendrocytes [62, 63]. In addition,
we found that the mPGK promoter is a strong promoter in
terms of transgene expression in the sensorimotor cortex;
mPGK promoter was superior over the hCMV and sCAG
promoters. Consistently, a study that compared AAV2
vectors containing the PGK and CMV promoters in the
mouse retina also observed that PGK was the stronger
promoter between the two [64].
The sCAG and hCMV promoters in AAV1 had relatively
weak transgene expression. These promoters could there-
fore be preferable for studies that require moderate to low
transgene expression in the CNS. The relatively low
expression by CMV and CAG promoters in some brain
regions has been reported before [65–67]. More specifically,
the CMV promoter has been reported to be silenced over
time with AAVs in piriform cortex [65], hippocampus
[65, 66] and substantia nigra [67]. It has also been reported
for the chicken β actin promoter, a large part of this DNA
sequence is identical to the sCAG promoter, to express
poorly in motor neurons of the spinal cord [68]. The
Table 1 Cellular tropism of
AAV1 with four different
promoters.
Cell type AAV1-sCAG AAV1-hCMV AAV1-mPGK AAV1-hSYN
Cortical neurons + + +++ +++
Layer V corticospinal neurons + + +++ +++
PNN-bearing interneurons + + +++ +++
Oligodendrocyte lineage ++ ++ + −
Astrocytes ++ ++ − −
Microglia − − − −
Shaded squares indicate that the AAV1 serotype and promoter initiate transgene expression in the mentioned
cell type; the plus signs (+) represent the amount of transduced cells for each viral vector. White squares
with the minus sign (−) illustrate that no transgene expression was observed in the mentioned cell type.
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relatively poor expression by the hCMV promoter in
cortical neurons could be caused by transcriptional inac-
tivation caused by epigenetic factors [69–71]. Investiga-
tion of expression levels at an earlier time point and
potential epigenetic silencing could shed some light on
this. However, such investigations were beyond the scope
of this study. Importantly, the promoters sCAG and
hCMV directed the expression of transgenes in astrocytes,
oligodendrocytes and cortical neurons including layer V
corticospinal neurons. The ubiquitous sCAG and hCMV
may therefore not be the ideal promoters for studies
aiming to transduce cortical neurons only. Many studies
support our findings that the hCMV and sCAG promoters
transduce astrocytes, oligodendrocytes and a restricted
number of cortical neurons in vivo. For instance, the
transduction of these cell types by the AAV1 serotype
with the CMV and CAG promoters have also been
observed by others [20, 21, 72]. Lentivirus containing the
hCMV and full-length CAG promoter also transduced
neurons, astrocytes and oligodendrocytes when injected
into the striatum [73]. The CMV promoter has been
reported to transduce astrocytes with high efficiency when
combined with AAV6 and AAV8 [23, 74]. The CMV
promoter has also been reported to activate transgenes in
astrocytes, oligodendrocytes and neurons with AAV5
[57], AAV8 [20] and AAV9 [75]. Another study reported
that the CAG promoter transduces these cell types with
the AAV8 serotype as well [76].
Microglia have been proven to be challenging to trans-
duce with AAVs in vivo (reviewed in [77]). We found that
the AAV1 serotype together with the promoters sCAG,
hCMV, mPGK and hSYN did not result in transgene
expression in microglia. AAV2 harbouring a CMV pro-
moter has been reported before to be unable to activate
transgenes in microglia [78]. Yet, AAV-mediated trans-
duction of microglia has been reported with a promoter
derived from the macrophage marker F4/80 or CD68 gene
[79–81]. This indicates that transduction of microglia is rare
using the common promoters with AAVs, and successful
transgene activation in these cells may require the identifi-
cation of microglia-specific promoters or another type of
viral vector for transgene delivery.
The current experiments do not shed light on the reason
why the mPGK and hSYN promoters drive high levels of
transgene expression and why the sCAG and hCMV pro-
moters are significantly weaker. The mPGK and hSYN
promoters contain regulatory elements that are recognized
by a combination of cellular transcription factors that are
normally involved in regulating the expression of the
phosphoglycerate kinase and synapsin genes in neurons.
One might therefore speculate that cellular promoters have
an advantage over viral-derived promoters because they
act in their natural context whereas viral promoters are
activated by (a set of) transcription factors that may not be
optimal drivers of transcription.
Conclusions
It is important for any gene therapy that transgenes are
delivered with high cell specificity and at adequate expression
levels. This study investigated the activity of four promoters
in a side-by-side comparison in mice and rats at 6 weeks after
AAV injection. The AAV1 serotype exhibited neuronal
tropism with all four investigated promoters. Yet, the choice
of promoter influences: (1) the strength of transgene expres-
sion; and (2) the type of cells that will express the transgene
of interest (Table 1).
AAV-mediated gene transfer for spinal cord injury
research will require robust expression of regeneration-
associated genes in neurons of the CST. The mPGK pro-
moter and hSYN promoters resulted in strong transgene
expression, while the commonly used hCMV and sCAG
had relatively weak expression in cortical neurons.
High cell specificity for layer V corticospinal neurons is
crucial to avoid unwanted side effects when delivering
regeneration-associated genes. These could be caused, for
instance, if the transgene alters gene expression in glia cells.
It is unclear how AAV-mediated gene transfer of
regeneration-associated genes will influence neurons other
than layer V corticospinal neurons. Manipulation of PNN-
bearing interneurons potentially affects the regeneration
response of layer V corticospinal neurons after injury. For
example, it has been shown that activation of interneurons
in the retina (amacrine cells) restrict neuronal survival and
axon regeneration of retinal ganglion cells after optic nerve
injury [82].
A promoter with robust and exclusive expression in layer
V corticospinal neurons is desired for spinal cord injury
experiments; however, to date, such a promoter has not yet
been identified. In this study, we showed that the hSYN
promoter has strong transgene expression and is specific to
neurons with no expression in glia cells. Based on the data
presented here, the AAV1 viral vector serotype and the
hSYN promoter is the optimal combination for transgene
delivery to the CST of mice and rats.
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